WEBULL
WebtradeDownload

What Is Driving Baxter International (BAX) After Its Latest Update?

Simply Wall St · 2d ago

Baxter International earnings swing back to profit

Baxter International (BAX) has just posted third quarter results that moved from a net loss a year ago to a net income of $294 million, alongside higher sales.

Management also raised full year 2026 earnings guidance, with expected reported sales growth from continuing operations now in the 4% to 5% range, up from a prior 3% to 4% outlook.

The earnings beat and higher 2026 guidance land after a choppy stretch for Baxter International’s investors, with the share price down 18.87% over the past 90 days but still up 17.95% year to date and supported by a 26.55% 1-year total shareholder return. However, longer term 3 and 5 year total shareholder returns remain deeply negative, suggesting recent momentum is rebuilding from a low base as the recovery story meets lingering concerns, including October’s FDA warning letter and the modest dividend affirmation.

Scan for other healthcare stocks where recent earnings shifts and guidance changes may be starting to reshape sentiment by using our hand picked 33 healthcare AI stocks as a comparative watchlist.

After a sharp 90 day slide but a stronger year to date and 1 year rebound, Baxter International now forces a choice. Investors can either lean into the recovery story at today’s price or wait and hope for a cheaper entry.

Most Popular Narrative: 15% Undervalued

Against a last close of $23.00, the most followed narrative pegs Baxter International’s fair value at $27.08, using an 8.89% discount rate and a detailed set of revenue, margin and earnings assumptions that tie back to 2029 estimates.

Analysts are assuming Baxter International's revenue will grow by 2.9% annually over the next 3 years.

Analysts assume that profit margins will increase from -5.3% today to 6.6% in 3 years time.

See why 19 investors see Baxter International as 15% undervalued.

Result: Fair Value of $27.08 (UNDERVALUED)

Still, the FDA warning letter on Baxter International’s Round Lake facility and the ongoing Novum IQ infusion pump field actions could pressure sentiment if remediation or resolutions drag.

Find out about the key risks to this Baxter International narrative.

Next Steps

Mixed signals around Baxter International can feel confusing, so move quickly, review the full dataset, then size up the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Baxter International?

Use the same energy you brought to researching Baxter International and put it to work hunting for other opportunities before they move without you.